Home Page | Photos | Video | Forum | Most Popular | Special Reports | Biz China Weekly
Make Us Your Home Page
Most Searched: flu season  water supply  H7N9   horsemeat scandal   SARS-like virus   

Abraxane improves survival in pancreatic cancer patients: Australian oncologist

English.news.cn   2014-01-21 10:49:18

SYDNEY, Jan. 21 (Xinhua) -- Abraxane, a chemotherapy drug for breast cancer, can be used in combination with the standard treatment to help pancreatic cancer patients live longer, an Australian study revealed on Tuesday.

Australian oncologist David Goldstein has presented the research findings at an American Society of Clinical Oncology conference in San Francisco, local media reported.

According to Goldstein, results from clinical trials of the drug combined with the standard treatment are encouraging.

The research found four percent of patients with advanced pancreatic cancer treated with the combination had survived for three years, compared with zero survival for those on only the standard treatment, gemcitabine.

The trial conducted at sites around the world involved 861 patients, including 120 Australians.

Each year, around 2,500 people are diagnosed with the deadly disease in Australia, with only six percent of them surviving five years.

Pancreatic cancer is hard to detect early and people diagnosed after it has spread are likely to die within six months.

Editor: Fu Peng
Related News
Home >> Health            
Most Popular English Forum  
Top News  >>
Follow Xinhua    Twitter    Facebook
Photos  >>
Video  >>
Top Science News Latest News  
  Special Reports  >>